source
- Roche’s divarasib shows survival benefit over Amgen and BMS drugs in KRAS G12C lung cancer trialRoche reported that its experimental KRAS G12C inhibitor divarasib extended overall survival and progression‑free survival in a Phase 3 head‑to‑head study against Amgen’s Lumakra and Bristol Myers…
- Celea Therapeutics raises $180 million to advance next-generation IPF drug deupirfenidoneCelea Therapeutics, a PureTech Health spinout, announced a $180 million venture round to fund development of its next-generation idiopathic pulmonary fibrosis (IPF) therapy, deupirfenidone. The ro…